SCHEMBL25406737

SCHEMBL25406737

O=C(NC(CO)c1ccccc1)c1ccnc(F)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 17/20 0.51
▸ MAPK13 O15264 1/20 0.51
▸ ROCK2 O75116 1/20 0.51
▸ RPS6KA5 O75582 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ PAK4 O96013 1/20 0.51
▸ PRKCG P05129 1/20 0.51
▸ CDK1 P06493 1/20 0.51
▸ PRKACA P17612 1/20 0.51
▸ RPS6KB1 P23443 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ AKT1 P31749 1/20 0.51
▸ AKT2 P31751 1/20 0.51
▸ CLK2 P49760 1/20 0.51
▸ GSK3A P49840 1/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ IRAK1 P51617 1/20 0.51
▸ RPS6KA3 P51812 1/20 0.51
▸ PRKX P51817 1/20 0.51
▸ NEK4 P51957 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30254858 1.00 MAPK1 (0.51) MAPK1MAPK13ROCK2RPS6KA5MAP4K4
SCHEMBL30341785 1.00 MAPK1 (0.51) MAPK1MAPK13ROCK2RPS6KA5MAP4K4
SCHEMBL30341569 0.81 TACR3 (0.54) MAPK1MAPK13ROCK2RPS6KA5MAP4K4
SCHEMBL23309543 0.81 TACR3 (0.54) MAPK1MAPK13ROCK2RPS6KA5MAP4K4
SCHEMBL25405435 0.80 MAPK1 (0.59) MAPK1MAPK13ROCK2RPS6KA5MAP4K4
SCHEMBL30341563 0.80 MAPK1 (0.59) MAPK1MAPK13ROCK2RPS6KA5MAP4K4
SCHEMBL29006563 0.80 ROCK2 (0.57) MAPK1ROCK2RPS6KA5PRKACAGSK3A
SCHEMBL30254982 0.80 ROCK2 (0.57) MAPK1ROCK2RPS6KA5PRKACAGSK3A
SCHEMBL30254834 0.80 ROCK2 (0.57) MAPK1ROCK2RPS6KA5PRKACAGSK3A
SCHEMBL25406671 0.74 ROCK2 (0.57) MAPK1MAPK13ROCK2RPS6KA5MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534456-B2 Heterocyclyl pyridines as novel fungicides BAYER AKTIENGESELLSCHAFT (DE) 2026-01-27 — — US disclosed
US-20230295138-A1 HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-21 — — US disclosed
CN-116157397-A Heterocyclylpyridines as novel fungicides 拜耳公司 2023-05-23 — — CN disclosed
EP-4161914-A1 HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES Bayer Aktiengesellschaft (DE) 2023-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295138-A1 HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES PNPO, CBR3, HPD MAPK1 1340/4885MAPK13 784/4885ROCK2 2871/4885
US-12534456-B2 Heterocyclyl pyridines as novel fungicides CBR1, CBR3, NOX1 MAPK1 855/4885MAPK13 2762/4885ROCK2 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback